乘聯會:3月全國新能源乘用車市場回暖 料銷量約57萬輛
乘聯會指,今年2月全國乘用車市場新能源銷量萬輛以上的10間廠商,批發銷量佔總體新能源乘用車全月銷量的83%,這些企業的3月預估銷量為47.7萬輛,按照正常結構佔比預測,3月的全國新能源乘用車銷量約在57萬輛。考慮到部分中小企業的新能源車銷量較2月改善較大,因此3月乘用車市場可偏向樂觀。
3月全國新能源乘用車市場雖然受到燃油車促銷潮影響,但仍保持回暖走勢。隨著近期碳酸鋰降價趨勢明顯,部分廠商一季度產銷主動減速,實現生產端降本。綜合預估,3月乘聯會新能源乘用車廠商批發銷量60萬輛,按月增長20%,按年增長30%。預計一季度新能源車廠商銷量148萬,按年增長25%,一季度新能源乘用車開門紅基本實現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.